r027 Search Results


fitc  (Sino Biological)
94
Sino Biological fitc
Fitc, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/r027/CD64+%2F+FCGR1+Antibody%2C+Rabbit+MAb/pmc13081479-44-2-8
Average 94 stars, based on 1 article reviews
fitc - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
csf  (Sino Biological)
93
Sino Biological csf
( A ) Design of <t>GPI-RBD-GM-CSF</t> fusion protein gene, ( B ) GPI-RBD-GM-CSF fusion protein binds both anti-RBD mAb and anti-GM-CSF mAb on CHO-S cell transfectants, ( C ) PIPLC treatment of CHO-S cells expressing GPI-RBD-GM-CSF reduced the level of expression, and ( D ) Flow cytometry analysis showed binding of human ACE-2 to GPI-RBD-GM-CSF fusion protein expressed in CHO-S cells.
Csf, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/r027/GM-CSF+%2F+CSF2+Antibody%2C+Rabbit+MAb/bio_rxiv__2022__02__01__478657-149-7-28
Average 93 stars, based on 1 article reviews
csf - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
bace 1 rabbit monoclonal antibody  (Sino Biological)
91
Sino Biological bace 1 rabbit monoclonal antibody
( A ) Design of <t>GPI-RBD-GM-CSF</t> fusion protein gene, ( B ) GPI-RBD-GM-CSF fusion protein binds both anti-RBD mAb and anti-GM-CSF mAb on CHO-S cell transfectants, ( C ) PIPLC treatment of CHO-S cells expressing GPI-RBD-GM-CSF reduced the level of expression, and ( D ) Flow cytometry analysis showed binding of human ACE-2 to GPI-RBD-GM-CSF fusion protein expressed in CHO-S cells.
Bace 1 Rabbit Monoclonal Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/r027/BACE1+Antibody%2C+Rabbit+MAb/pm37558026-75-11-19
Average 91 stars, based on 1 article reviews
bace 1 rabbit monoclonal antibody - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier

Image Search Results


( A ) Design of GPI-RBD-GM-CSF fusion protein gene, ( B ) GPI-RBD-GM-CSF fusion protein binds both anti-RBD mAb and anti-GM-CSF mAb on CHO-S cell transfectants, ( C ) PIPLC treatment of CHO-S cells expressing GPI-RBD-GM-CSF reduced the level of expression, and ( D ) Flow cytometry analysis showed binding of human ACE-2 to GPI-RBD-GM-CSF fusion protein expressed in CHO-S cells.

Journal: bioRxiv

Article Title: Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

doi: 10.1101/2022.02.01.478657

Figure Lengend Snippet: ( A ) Design of GPI-RBD-GM-CSF fusion protein gene, ( B ) GPI-RBD-GM-CSF fusion protein binds both anti-RBD mAb and anti-GM-CSF mAb on CHO-S cell transfectants, ( C ) PIPLC treatment of CHO-S cells expressing GPI-RBD-GM-CSF reduced the level of expression, and ( D ) Flow cytometry analysis showed binding of human ACE-2 to GPI-RBD-GM-CSF fusion protein expressed in CHO-S cells.

Article Snippet: Expression of both the S1 RBD and GM-CSF on the surface of transfected CHO-S cells was confirmed by flow cytometry using fluorophore conjugated antibodies against RBD, Clone MM57 (Sino Biologicals) and GM-CSF, Clone MP1-22E9 (BioLegend).

Techniques: Expressing, Flow Cytometry, Binding Assay

( A ) Colloidal blue (lane 1), and Western blot (lanes 2-7) of the immunoaffinity column purified fusion protein from CHO-S cells probed with anti-RBD antibody (lanes 3 & 4), or anti-GM-CSF mAb (lanes 6 & 7). Lane 2 is control RBD probed with anti-RBD Ab, and lane 5 is control GM-CSF probed with anti-GM-CSF antibody. ( B ) ELISA for GPI-RBD-GM-CSF binding to antibodies in the human COVID-19 patients’ sera, and ( C) ELISA of purified GPI-RBD-GM-CSF binding to ACE-2. ( D ) FACS analysis of VLPs incorporated with GPI-IL-12 and GPI-RBD-GM-CSF fusion protein by protein transfer, and ( E ) BMDC proliferation by GPI-GM-CSF, GPI-RBD-GM-CSF and hybrid vaccine.

Journal: bioRxiv

Article Title: Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

doi: 10.1101/2022.02.01.478657

Figure Lengend Snippet: ( A ) Colloidal blue (lane 1), and Western blot (lanes 2-7) of the immunoaffinity column purified fusion protein from CHO-S cells probed with anti-RBD antibody (lanes 3 & 4), or anti-GM-CSF mAb (lanes 6 & 7). Lane 2 is control RBD probed with anti-RBD Ab, and lane 5 is control GM-CSF probed with anti-GM-CSF antibody. ( B ) ELISA for GPI-RBD-GM-CSF binding to antibodies in the human COVID-19 patients’ sera, and ( C) ELISA of purified GPI-RBD-GM-CSF binding to ACE-2. ( D ) FACS analysis of VLPs incorporated with GPI-IL-12 and GPI-RBD-GM-CSF fusion protein by protein transfer, and ( E ) BMDC proliferation by GPI-GM-CSF, GPI-RBD-GM-CSF and hybrid vaccine.

Article Snippet: Expression of both the S1 RBD and GM-CSF on the surface of transfected CHO-S cells was confirmed by flow cytometry using fluorophore conjugated antibodies against RBD, Clone MM57 (Sino Biologicals) and GM-CSF, Clone MP1-22E9 (BioLegend).

Techniques: Western Blot, Purification, Control, Enzyme-linked Immunosorbent Assay, Binding Assay

ELISA plates were coated with GPI-RBD-GM-CSF and serum samples from various groups of mice (n=5) immunized with GPI-RBD-GM-CSF, VLP vaccine containing the GPI-RBD-GM-CSF or hybrid vaccine (VLP vaccine containing the GPI-RBD-GM-CSF + GPI-IL-12) were diluted and added to the wells after blocking the plates. (A) Total IgG levels 6 weeks after booster dose, and (B) IgG isotype in the sera 10 weeks after the booster dose. Anti-mouse IgG (A) or isotype specific anti-mouse IgG-HRP conjugate (B) was used to detect the bound antibody.

Journal: bioRxiv

Article Title: Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

doi: 10.1101/2022.02.01.478657

Figure Lengend Snippet: ELISA plates were coated with GPI-RBD-GM-CSF and serum samples from various groups of mice (n=5) immunized with GPI-RBD-GM-CSF, VLP vaccine containing the GPI-RBD-GM-CSF or hybrid vaccine (VLP vaccine containing the GPI-RBD-GM-CSF + GPI-IL-12) were diluted and added to the wells after blocking the plates. (A) Total IgG levels 6 weeks after booster dose, and (B) IgG isotype in the sera 10 weeks after the booster dose. Anti-mouse IgG (A) or isotype specific anti-mouse IgG-HRP conjugate (B) was used to detect the bound antibody.

Article Snippet: Expression of both the S1 RBD and GM-CSF on the surface of transfected CHO-S cells was confirmed by flow cytometry using fluorophore conjugated antibodies against RBD, Clone MM57 (Sino Biologicals) and GM-CSF, Clone MP1-22E9 (BioLegend).

Techniques: Enzyme-linked Immunosorbent Assay, Blocking Assay

ELISA plates were coated with inactivated influenza A/PR8 H1N1. Serum samples from mice vaccinated with VLP, VLP with GPI-GM-CSF and GPI-IL-12 or hybrid vaccine were serially diluted (5-fold) and added to the wells after blocking the plates. ( A ) total IgG, ( B ) IgG1 or ( C ) IgG2a antibody response. Isotype specific anti-mouse Ig-HRP conjugate was used to detect the isotype of the antibody bound. * p<0.05

Journal: bioRxiv

Article Title: Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

doi: 10.1101/2022.02.01.478657

Figure Lengend Snippet: ELISA plates were coated with inactivated influenza A/PR8 H1N1. Serum samples from mice vaccinated with VLP, VLP with GPI-GM-CSF and GPI-IL-12 or hybrid vaccine were serially diluted (5-fold) and added to the wells after blocking the plates. ( A ) total IgG, ( B ) IgG1 or ( C ) IgG2a antibody response. Isotype specific anti-mouse Ig-HRP conjugate was used to detect the isotype of the antibody bound. * p<0.05

Article Snippet: Expression of both the S1 RBD and GM-CSF on the surface of transfected CHO-S cells was confirmed by flow cytometry using fluorophore conjugated antibodies against RBD, Clone MM57 (Sino Biologicals) and GM-CSF, Clone MP1-22E9 (BioLegend).

Techniques: Enzyme-linked Immunosorbent Assay, Blocking Assay

BALB/c mice (n=10; 2-3 months old) administered with hybrid vaccine, hybrid vaccine without IL-12 (VLP RG) or VLP in 50 ul volume via intramuscular route. Control mice received either PBS or influenza VLP. Booster dose given on d33, and blood was collected 2 weeks later (week 7). Mice were challenged with influenza A/PR8 H1N1 virus (n=5) or mouse adapted SARS-CoV2 (n=5) 16-18 weeks after the first dose. ( A ) Neutralizing antibodies titers in the serum of BALB/c mice (n=5-6 per group). Serum collected from BALB/c mice 2 weeks after booster dose was serially diluted from 1:4 to 1:1024 and PRNT was conducted against SARS-CoV-2 (Wuhan virus). ( B ) BALB/c mice were inoculated intranasally with mouse-adapted SARS-CoV-2 (10 5 plaque-forming units) 3 months after booster dose. Percentage of daily body weight change in the animals. ( C ) The RNA levels of SARS-CoV-2 were determined in the lungs by qRT-PCR (n=4-5 per group). Error bars represent SEM. The data are expressed as genome copies/μg of RNA. Each data point represents an individual mouse. Data are expressed as mean log 10 titer. * p<0.05; ** p <0.01 ***p<0.001. VLP RG: VLP incorporated with GPI-RBD-GM-CSF; hybrid vaccine: VLP incorporated with GPI-RBD-GM-CSF and GPI-IL-12.

Journal: bioRxiv

Article Title: Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

doi: 10.1101/2022.02.01.478657

Figure Lengend Snippet: BALB/c mice (n=10; 2-3 months old) administered with hybrid vaccine, hybrid vaccine without IL-12 (VLP RG) or VLP in 50 ul volume via intramuscular route. Control mice received either PBS or influenza VLP. Booster dose given on d33, and blood was collected 2 weeks later (week 7). Mice were challenged with influenza A/PR8 H1N1 virus (n=5) or mouse adapted SARS-CoV2 (n=5) 16-18 weeks after the first dose. ( A ) Neutralizing antibodies titers in the serum of BALB/c mice (n=5-6 per group). Serum collected from BALB/c mice 2 weeks after booster dose was serially diluted from 1:4 to 1:1024 and PRNT was conducted against SARS-CoV-2 (Wuhan virus). ( B ) BALB/c mice were inoculated intranasally with mouse-adapted SARS-CoV-2 (10 5 plaque-forming units) 3 months after booster dose. Percentage of daily body weight change in the animals. ( C ) The RNA levels of SARS-CoV-2 were determined in the lungs by qRT-PCR (n=4-5 per group). Error bars represent SEM. The data are expressed as genome copies/μg of RNA. Each data point represents an individual mouse. Data are expressed as mean log 10 titer. * p<0.05; ** p <0.01 ***p<0.001. VLP RG: VLP incorporated with GPI-RBD-GM-CSF; hybrid vaccine: VLP incorporated with GPI-RBD-GM-CSF and GPI-IL-12.

Article Snippet: Expression of both the S1 RBD and GM-CSF on the surface of transfected CHO-S cells was confirmed by flow cytometry using fluorophore conjugated antibodies against RBD, Clone MM57 (Sino Biologicals) and GM-CSF, Clone MP1-22E9 (BioLegend).

Techniques: Control, Virus, Quantitative RT-PCR

BALB/c mice administered with hybrid vaccine (10 μg/dose) or hybrid vaccine without GPI-IL-12 (VLP RG) as described in . Booster dose given after 33 days of the first dose. ( A ) HAI titer in the blood 2 weeks after the booster dose (day 48). Lung viral titer ( B ) and survival ( C ) of mice challenged with influenza A/PR8 H1N1 virus 3 months after the booster dose. Inoculation dose was 10 times LD50. VLP RG: VLP incorporated with GPI-RBD-GM-CSF; Hybrid vaccine: VLP incorporated with GPI-RBD-GM-CSF and GPI-IL-12. Statistical significance was calculated by one-way ANOVA and Dunnett’s post-multiple comparison tests. Error bars indicate the mean ± standard errors of the mean (SEM). ***; p < 0.001, ns; not significant

Journal: bioRxiv

Article Title: Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

doi: 10.1101/2022.02.01.478657

Figure Lengend Snippet: BALB/c mice administered with hybrid vaccine (10 μg/dose) or hybrid vaccine without GPI-IL-12 (VLP RG) as described in . Booster dose given after 33 days of the first dose. ( A ) HAI titer in the blood 2 weeks after the booster dose (day 48). Lung viral titer ( B ) and survival ( C ) of mice challenged with influenza A/PR8 H1N1 virus 3 months after the booster dose. Inoculation dose was 10 times LD50. VLP RG: VLP incorporated with GPI-RBD-GM-CSF; Hybrid vaccine: VLP incorporated with GPI-RBD-GM-CSF and GPI-IL-12. Statistical significance was calculated by one-way ANOVA and Dunnett’s post-multiple comparison tests. Error bars indicate the mean ± standard errors of the mean (SEM). ***; p < 0.001, ns; not significant

Article Snippet: Expression of both the S1 RBD and GM-CSF on the surface of transfected CHO-S cells was confirmed by flow cytometry using fluorophore conjugated antibodies against RBD, Clone MM57 (Sino Biologicals) and GM-CSF, Clone MP1-22E9 (BioLegend).

Techniques: Virus, Comparison